Jawaid Shagufta, Joshi Yogesh, Neelofar Nauroz, Khursheed Khuzamah, Shams Samya, Chaudhary Mansi, Arora Mitali, Mahajan Karan, Anwar Firoz
Department of Pharmacy Practice, School of Pharmaceutical Sciences, Shri Guru Ram Rai University, Dehradun, Uttarakhand, India.
Department of Obstetrics and Gynae, Himaliyan Institute of Medical Sciences, Swami Rama Himaliyan University, Jollygrand, Dehradun, Uttarakhand, India.
Curr Pharm Des. 2025;31(10):741-752. doi: 10.2174/0113816128347223241021111914.
Cardiovascular Diseases (CVDs) are the leading cause of global morbidity and mortality, necessitating innovative approaches for both therapeutics and diagnostics. Nanoscience has emerged as a promising frontier in addressing the complexities of CVDs.
This study aims to explore the interaction of CVDs and Nanomedicine (NMs), focusing on applications in therapeutics and diagnostics.
In the realm of therapeutics, nanosized drug delivery systems exhibit unique advantages, such as enhanced drug bioavailability, targeted delivery, and controlled release. NMs platform, including liposomes, nanoparticles, and carriers, allows the precise drug targeting to the affected cardiovascular tissues with minimum adverse effects and maximum therapeutic efficacy. Moreover, Nanomaterial (NM) enables the integration of multifunctional components, such as therapeutic agents and target ligands, into a single system for comprehensive CVD management. Diagnostic fronts of NMs offer innovative solutions for early detection and monitoring of CVDs. Nanoparticles and nanosensors enable highly sensitive and specific detection of Cardiac biomarkers, providing valuable insights into a disease state, its progression, therapeutic outputs, etc. Further, nano-based technology via imaging modalities offers high high-resolution imaging, aiding in the vascularization of cardiovascular structures and abnormalities. Nanotechnology-based imaging modalities offer high-resolution imaging and aid in the visualization of cardiovascular structures and abnormalities.
The cross-talk of CVDs and NMs holds tremendous potential for revolutionizing cardiovascular healthcare by providing targeted and efficient therapeutic interventions, as well as sensitive and early detection for the improvement of patient health if integrated with Artificial Intelligence (AI).
心血管疾病（CVDs）是全球发病和死亡的主要原因，因此需要创新的治疗和诊断方法。纳米科学已成为解决心血管疾病复杂性的一个有前景的前沿领域。
本研究旨在探讨心血管疾病与纳米医学（NMs）的相互作用，重点关注其在治疗和诊断中的应用。
在治疗领域，纳米级药物递送系统具有独特优势，如提高药物生物利用度、靶向递送和控释。纳米医学平台，包括脂质体、纳米颗粒和载体，能够将药物精确靶向到受影响的心血管组织，同时副作用最小且治疗效果最佳。此外，纳米材料能够将多功能成分，如治疗剂和靶向配体，整合到一个单一系统中，以实现对心血管疾病的综合管理。纳米医学的诊断前沿为心血管疾病的早期检测和监测提供了创新解决方案。纳米颗粒和纳米传感器能够对心脏生物标志物进行高度灵敏和特异的检测，为疾病状态、其进展、治疗效果等提供有价值的见解。此外，基于纳米技术通过成像方式可提供高分辨率成像，有助于观察心血管结构和异常情况。
心血管疾病与纳米医学的相互作用具有巨大潜力，通过提供靶向和高效的治疗干预措施，以及与人工智能（AI）结合实现敏感和早期检测，从而彻底改变心血管医疗保健，改善患者健康状况。
